SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 4/25/2017 10:25:05 AM - Followers: 825 - Board type: Free - Posts Today: 61

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:48:03 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:42:25 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:27:37 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:19:06 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:10:49 PM
PostSubject
#248717  Sticky Note Elite Pharmaceuticals is starting to look a lot IB_ 03/31/17 01:32:55 PM
#247416  Sticky Note HERE is WHAT long term investors need to UNDERSTAND!!! Couch 03/21/17 06:12:24 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#251753   No one is buying either, will find out stockboy 04/25/17 10:39:35 AM
#251752   I would bet that those sophisticated independent experts Dr PeteRose MLB 04/25/17 10:25:05 AM
#251751   Yep range bound with no one selling at Gman24 04/25/17 10:21:57 AM
#251750   Elite drowning in a SEA of GREEN too stockboy 04/25/17 10:16:30 AM
#251749   Sungen's two clinical trials before earnings call? snupoled 04/25/17 10:16:20 AM
#251748   We most certainly do not agree. mrwrn2010 04/25/17 10:10:34 AM
#251747   Everyone knows the company was built on solid Couch 04/25/17 09:57:56 AM
#251745   scammy, NOW that is a word to describe dr_lowenstein 04/25/17 09:52:51 AM
#251744   Thank you for your EXPERT analysis always look stockboy 04/25/17 09:50:03 AM
#251743   interesting, but fundamentally flawed. A company is valued dr_lowenstein 04/25/17 09:47:59 AM
#251742   Based on a comparison between Flexion and Elite, Couch 04/25/17 09:47:38 AM
#251741   Always, soon, never - famous words on the Couch 04/25/17 09:42:27 AM
#251740   LMAO; no the OTC is sub pennies are Couch 04/25/17 09:41:16 AM
#251739   Thanks N2k.. always on point.. we're sitting on Gman24 04/25/17 09:37:15 AM
#251738   Boom! Thanks for the fact-based analysis. mrwrn2010 04/25/17 09:33:45 AM
#251737   Great post ! NASDAQ2020 04/25/17 09:33:12 AM
#251736   All insiders,not just Nasrat have held all their Gman24 04/25/17 09:32:54 AM
#251735   I mentioned a few days ago that there no2koolaid 04/25/17 09:30:50 AM
#251734   Probably not for scammy companies. Good thing Elite mrwrn2010 04/25/17 09:28:34 AM
#251733   No sub-pennies? Thought that's been the claim for years? mrwrn2010 04/25/17 09:23:19 AM
#251732   That always works on the OTC. John_Langston 04/25/17 09:21:58 AM
#251731   Nasrat held his 150+ million shares as well. mrwrn2010 04/25/17 09:20:18 AM
#251730   That's the OTC, $2 dollars and $38 dollars John_Langston 04/25/17 09:00:05 AM
#251729   Yeah and the new 52 week low was Couch 04/25/17 08:56:58 AM
#251728   I wish I could say the same for John_Langston 04/25/17 08:55:35 AM
#251727   Yeah I agree .02 cents "almost" happened yesterday. Couch 04/25/17 08:54:22 AM
#251726   11 Pathways to DollarLand and Beyond NASDAQ2020 04/25/17 08:48:59 AM
#251725   It sure does look more promising than $2 John_Langston 04/25/17 08:44:39 AM
#251724   LMAO; like I said .02 cents was coming Couch 04/25/17 08:39:25 AM
#251723   I agree the .02's will be here yesterday Couch 04/25/17 08:38:03 AM
#251722   LMAO; like I said "there is no way John_Langston 04/25/17 08:36:52 AM
#251721   I agree there is no way in hell John_Langston 04/25/17 08:34:55 AM
#251720   LMAO; like I said I'm still waiting for Couch 04/25/17 08:32:51 AM
#251719   Everything good for $ELTP in May 2017. John_Langston 04/25/17 08:32:32 AM
#251718   I agree the stock has $2 multiple times Couch 04/25/17 08:31:55 AM
#251717   Go back and read my many posts that John_Langston 04/25/17 08:31:30 AM
#251716   Yes we all see that now. John_Langston 04/25/17 08:30:15 AM
#251715   THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 04/25/17 08:29:49 AM
#251714   HERE is WHAT long term investors need to Couch 04/25/17 08:24:09 AM
#251713   I was also told it wouldn't see the stockboy 04/25/17 08:23:34 AM
#251712   Everything good for $ELTP in May 2017. lasers 04/25/17 08:20:21 AM
#251711   Still waiting for proof from the TA that Couch 04/25/17 08:19:05 AM
#251710   No like the Elite TA isn't gagged when John_Langston 04/25/17 08:17:36 AM
#251709   That's why I bought millions of shares at John_Langston 04/25/17 08:13:20 AM
#251708   And my bet is that the .02 will Couch 04/25/17 08:01:23 AM
#251707   My bet was there was no way in John_Langston 04/25/17 08:00:27 AM
#251706   Huh you mean the PPS has hit $2 Couch 04/25/17 08:00:23 AM
#251705   just tell more lies. Couch 04/25/17 07:59:07 AM
#251704   No that was $2.00 dollars a share. John_Langston 04/25/17 07:58:11 AM
#251703   what the plan B is with IR. John_Langston 04/25/17 07:56:43 AM
PostSubject